论文信息 - The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease - 字舞流文

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease

J. Gisbert | M. Matucci-Cerinic | A. Dignass | K. Gaffney | D. Jadon | P. Carron | J. Addison | I. Pande | Maximilian Utzinger | U. Müller-Ladner | T. Lobatón